OnKure Therapeutics Research and Development Expenses 2020-2024 | OKUR

OnKure Therapeutics research and development expenses from 2020 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

OnKure Therapeutics Research and Development Expenses 2020-2024 | OKUR

OnKure Therapeutics research and development expenses from 2020 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.1B
Takeda Pharmaceutical (TAK)$44.8B
Merck (MKGAF)$21.8B
Astellas Pharma (ALPMY)$20.6B
Sandoz Group AG (SDZNY)$18.4B
Summit Therapeutics (SMMT)$17B
United Therapeutics (UTHR)$16.5B
Shionogi (SGIOY)$12.2B
Neurocrine Biosciences (NBIX)$12B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Jazz Pharmaceuticals (JAZZ)$7.1B
Ionis Pharmaceuticals (IONS)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.9B
Crinetics Pharmaceuticals (CRNX)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.7B
Dyne Therapeutics (DYN)$3.6B
PTC Therapeutics (PTCT)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$2B
Harrow (HROW)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Ocular Therapeutix (OCUL)$1.8B
NewAmsterdam Pharma (NAMS)$1.7B
ARS Pharmaceuticals (SPRY)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B